Drug Trial Radar · NCT04707248
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
179
Actual
Start
Dec 22, 2020
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.
Conditions
- Renal Cell Carcinoma
- Ovarian Tumor
Interventions
DS-6000aDrug
Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
DS-6000aDrug
Intravenous administration at RDE on Day 1 of Cycle 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting toxicities (DLTs)Time frame: Day 1 to Day 21 in Cycle 1 (each cycle is 21 days)
- Number of Participants Reporting Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special InterestTime frame: From start of treatment up to 40 days after last dose, up to approximately 52 months
- Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (Dose Expansion)Time frame: From start of treatment (Cycle 1, Day 1) up to disease progression, up to approximately 52 months (each cycle is 21 days)
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC HOPE (A)A HOPE)
Tucson, Arizona
Rocky Mountain Cancer Center
Denver, Colorado
Florida Cancer Lake Mary
Lake Mary, Florida
Oklahoma University
Oklahoma City, Oklahoma
SCRI Oncology Partners
Nashville, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
National Hospital Organization Kyusyu Cancer Center
Fukuoka, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Kōtoku, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Japan
Shizuoka Cancer Center
Nakatogari, Japan
Saitama Medical University International Medical Center
Saitama, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
National Cancer Center Hospital East
Kashiwa-shi, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.